Journal Home
Search for

Volume 89, Issue 5, Pages 1209-1212 (May 2008)


View previous. 27 of 57 View next.

Anastrozole or letrozole for ovulation induction in clomiphene-resistant women with polycystic ovarian syndrome: a prospective randomized trial

Ahmed Badawy, M.D.aCorresponding Author Informationemail address, Abeer Mosbah, M.D.b, Magda Shady, M.D.c

Received 12 March 2007; received in revised form 27 April 2007; accepted 2 May 2007. published online 09 August 2007.

Objective

To compare the effects of letrozole (2.5 mg) and anastrozole (1 mg) meant for ovulation induction in clomiphene (CC)-resistant women with PCOS.

Design

Prospective randomized trial.

Setting

University teaching hospital and private practice setting.

Patient(s)

The study comprised a total of 220 infertile women (574 cycles) with CC-resistant PCOS.

Intervention(s)

Patients were randomized to treatment with 2.5 mg of letrozole daily (111 patients, 295 cycles) or 1 mg of anastrozole daily (109 patients, 279 cycles) for 5 days from day 3 of menses.

Main Outcome Measure(s)

Number of follicles, serum E2, serum P, endometrial thickness, pregnancy rate (PR), and miscarriage rate.

Result(s)

The total number of follicles was significantly more in the anastrozole group (5.4 ± 0.4 vs. 5.8 ± 0.4). The number of follicles ≥14 mm (3.1 ± 0.3 vs. 2.7 ± 0.2) and ≥18 mm (2.3 ± 0.1 vs. 3.1 ± 0.2) were significantly higher in the anastrozole group. The endometrial thickness at the time of hCG administration was significantly more in the anastrozole group (9.1 ± 0.2 vs. 10.2 ± 0.7 mm). The duration to reach a dominant follicle was longer in the letrozole group (12.1 ± 1.3 days vs. 8.8 ± 1.9 days) but without statistical significant difference. Ovulation occurred in 183/295 cycles (62%) in the letrozole group and 177/279 cycles (63.4%) in the anastrozole group, whereas pregnancy occurred in 36/295 cycles (12.2%) in the letrozole group and 42/279 cycles (15.1%) in the anastrozole group and the differences were not statistically significant.

Conclusion(s)

The results of this study did not show a significant difference in PR or miscarriage rate between anastrozole and letrozole when used for ovulation induction in women with CC-resistant PCOS.

Key WordsLetrozole, anastrozole, PCOS

a Department of Obstetrics & Gynecology, Mansoura University, Mansoura, Egypt

b Department of Clinical Pathology, Mansoura University, Mansoura, Egypt

c Department of Radiology, Mansoura University, Mansoura, Egypt

Corresponding Author InformationReprint requests: Ahmed Badawy, M.D., M.R.C.O.G., Department of Obstetrics & Gynecology, Mansoura University Hospitals, Mansoura, Egypt (FAX: 20502303939).

PII: S0015-0282(07)01038-2

doi:10.1016/j.fertnstert.2007.05.010


View previous. 27 of 57 View next.